MedTrace Logo

Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency

NCT03667300 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2019-09-23

No results posted yet for this study

Summary

In this multi-center, randomized, double-blind, active-controlled, phase II non-inferiority study, we aimed to test the non-inferiority of evogliptin vs linagliptin in terms of reduction of albuminuria at week 24 from baseline in patients with type 2 diabetes having renal insufficiency.

Conditions

  • Type2 Diabetes Mellitus
  • Albuminuria
  • Renal Insufficiency

Interventions

DRUG

Evogliptin

This group will take daily evogliptin 5mg per oral, not linagliptin.

DRUG

Linagliptin

This group will take daily linagliptin 5mg per oral, not evogliptin

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jae Hyeon Kim, MD PhD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-16
Primary Completion
2019-05-14
Completion
2019-05-14

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03667300 on ClinicalTrials.gov